Endometrial Cancer Clinical Trials in Washington D.C., District of Columbia

8 studies are recruiting for endometrial cancer in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

   The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxoru…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Washington Hospital Center, Washington D.C., District of Columbia

   Locations

   191 in total

   Run by

   BioNTech SE

   See if you can join NCT06340568 on ClinicalTrials.gov

2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

   Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Washington Hospital Center ( Site 5005), Washington D.C., District of Columbia

   Locations

   264 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06952504 on ClinicalTrials.gov

3. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

   The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Washington Hospital, Washington D.C., District of Columbia

   Locations

   171 in total

   Run by

   Genmab

   See if you can join NCT07166094 on ClinicalTrials.gov

4. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

5. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Washington D.C., District of Columbia

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

6. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

   This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Washington D.C., District of Columbia

   Locations

   320 in total

   Run by

   AstraZeneca

   See if you can join NCT07044336 on ClinicalTrials.gov

7. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

   This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Medstar Georgetown Cancer Institute, Washington D.C., District of Columbia

   Locations

   21 in total

   Run by

   Alliance Foundation Trials, LLC.

   See if you can join NCT04486352 on ClinicalTrials.gov

8. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov